ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief
Zosano Pharma, Inc. Announces Funding Close Totaling $90 Million FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products using innovative drug delivery, has announced the receipt of the second half of
Macroflux Announces Name Change to Zosano Pharma, Inc. FREMONT, Calif.--(BUSINESS WIRE)--Sept. 27, 2007--The Macroflux Corporation announced today that it has changed the name of the company to Zosano Pharma, Inc. "Our name change reflects the positive evolutionary steps the company is taking to
Macroflux Names M. Cory Zwerling President, CEO Macroflux, an emerging specialty pharmaceutical company focused on the development of proprietary products, has named M. Cory Zwerling President and CEO of the company. “This is an exciting opportunity to lead Macroflux with a strong team,
Launch of Macroflux Corporation
Macroflux Corporation has raised $75 million in an equity financing to create a new transdermal drug development company.
